|
ES2059571T3
(es)
|
1988-01-19 |
1994-11-16 |
Takeda Chemical Industries Ltd |
Fumagilina como agente angiostatico.
|
|
DE68915900T2
(de)
|
1988-09-01 |
1994-11-24 |
Childrens Medical Center |
Angiogenese hemmendes Mittel.
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
US9707302B2
(en)
*
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20090275619A1
(en)
|
2006-04-03 |
2009-11-05 |
BOUERES Julia |
Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
|
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
AU2008321382A1
(en)
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
|
|
WO2009064738A2
(en)
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
|
EP2240466B1
(en)
|
2008-01-08 |
2015-07-29 |
Merck Sharp & Dohme Limited |
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
US9078864B2
(en)
|
2008-01-08 |
2015-07-14 |
Akthelia Pharmaceuticals |
Agonists for antimicrobial peptide systems
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
AR075239A1
(es)
|
2009-02-04 |
2011-03-16 |
Bipar Sciences Inc |
Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
WO2011153383A1
(en)
|
2010-06-04 |
2011-12-08 |
Bipar Science, Inc. |
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
|
|
EP3327148B1
(en)
|
2010-06-18 |
2021-03-17 |
Myriad Genetics, Inc. |
Methods of predicting the status of brca1 and brca2 genes in a cancer cell
|
|
ES2704303T3
(es)
|
2010-08-24 |
2019-03-15 |
Dana Farber Cancer Inst Inc |
Procedimientos para la predicción de una respuesta contra el cáncer
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
CA2867434C
(en)
|
2012-06-07 |
2021-10-12 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
EP2928473B1
(en)
|
2012-12-07 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Regioselective n-2 arylation of indazoles
|
|
DK2928865T3
(en)
|
2012-12-07 |
2018-06-18 |
Merck Sharp & Dohme |
BIOCATALYTIC TRANSAMINATION PROCEDURE
|
|
WO2014138101A1
(en)
|
2013-03-04 |
2014-09-12 |
Board Of Regents, The University Of Texas System |
Gene signature to predict homologous recombination (hr) deficient cancer
|
|
US20150071910A1
(en)
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA2931181C
(en)
|
2013-12-09 |
2023-01-24 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
JP6663350B2
(ja)
|
2014-01-16 |
2020-03-11 |
クロヴィス・オンコロジー，インコーポレーテッド |
ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
|
|
US20170175197A1
(en)
*
|
2014-01-29 |
2017-06-22 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
JP6648040B2
(ja)
|
2014-05-28 |
2020-02-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
WO2016176503A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
SG10201913073YA
(en)
|
2015-08-20 |
2020-03-30 |
Ipsen Biopharm Ltd |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
CN108883115A
(zh)
|
2015-10-26 |
2018-11-23 |
麦迪韦逊科技有限责任公司 |
用parp抑制剂治疗小细胞肺癌
|
|
WO2017142871A1
(en)
|
2016-02-15 |
2017-08-24 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
|
HRP20240136T1
(hr)
|
2016-06-29 |
2024-04-12 |
Tesaro, Inc. |
Metode liječenja raka jajnika
|
|
US11202782B2
(en)
*
|
2016-09-27 |
2021-12-21 |
Beigene, Ltd. |
Treatment cancers using a combination comprising PARP inhibitors
|
|
MA50677A
(fr)
|
2016-11-01 |
2021-07-14 |
Anaptysbio Inc |
Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
|
|
CN110049777A
(zh)
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
AU2018205401B2
(en)
|
2017-01-09 |
2025-01-02 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
AU2018246214B2
(en)
|
2017-03-27 |
2021-07-08 |
Merck Sharp & Dohme Llc |
Niraparib compositions
|
|
EP3606523A1
(en)
|
2017-03-27 |
2020-02-12 |
Tesaro, Inc. |
Niraparib formulations
|
|
WO2018200517A1
(en)
|
2017-04-24 |
2018-11-01 |
Tesaro, Inc. |
Methods of manufacturing of niraparib
|
|
TWI791519B
(zh)
|
2017-04-27 |
2023-02-11 |
美商提薩羅有限公司 |
針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
|
|
TW202444417A
(zh)
|
2017-05-09 |
2024-11-16 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
CN110913911A
(zh)
|
2017-05-18 |
2020-03-24 |
特沙诺有限公司 |
用于治疗癌症的组合疗法
|
|
US20200129482A1
(en)
|
2017-06-26 |
2020-04-30 |
Abbvie Inc. |
Treatment of non-small cell lung cancer
|
|
CN111278433A
(zh)
|
2017-09-26 |
2020-06-12 |
特沙诺有限公司 |
尼拉帕尼制剂
|
|
WO2019067978A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
POLYTHERAPIES FOR THE TREATMENT OF CANCER
|
|
US11801240B2
(en)
|
2017-10-06 |
2023-10-31 |
Tesaro, Inc. |
Combination therapies and uses thereof
|
|
TW201929902A
(zh)
|
2017-12-27 |
2019-08-01 |
美商提薩羅有限公司 |
治療癌症之方法
|
|
BR112020015909A2
(pt)
|
2018-02-05 |
2020-12-15 |
Tesaro, Inc. |
Formulações pediátricas de niraparib e métodos de tratamento pediátrico
|
|
EA201992594A1
(ru)
|
2018-03-26 |
2020-03-20 |
Тесаро, Инк. |
Комбинированные терапии для лечения рака
|
|
US11970530B2
(en)
|
2020-08-13 |
2024-04-30 |
Astrazeneca Ab |
Methods of treating homologous recombination deficient cancer
|